

King, Valerie A.

From: Kimberly Prchal [Kimberly.Prchal@mdsps.com]
Sent: Friday, February 14, 2003 5:24 PM
To: Hans-Juergen.Roethig@pmusa.com; martin.unverdorben@pmusa.com;
Bettie.L.Nelson@pmusa.com; Jan.Oey@pmusa.com; Mohamadi.Sarkar@pmusa.com;
valerie.a.king@pmusa.com; paul.mendes@pmusa.com
Cc: Michael Szwaneke; Chad Briscoe; Peggy Ruhn; Nancy Wang; Henry Cheng; Yuli Xie; Megan
Mccrory; Robert Earl; Philip Bach; James Cunningham; Mary Hetrick
Subject: Re: Study Dates
Sensitivity: Confidential

All,

Phil has provided me with September 2003 dates for a possible 10-day study.
The study would begin on 18 Sep and end on 29 Sep.

Thanks
Kim

Kimberly M. Prchal
Senior Project Manager
MDS Pharma Services - Lincoln, NE
kimberly.prchal@mdsps.com
402.437.4773

All,

Attached are the revised study dates for the short-term Series K studies. The
initial study SeriesK/01/03 (AA02981) has been moved to June 2003. The second
study SeriesK/02/03 (AA03468) has been moved to August 2003. IRB dates and
final document receipt have also been included.

Also attached are the confirmed dates for the short-term ACCORD JLI Menthol
study (ECHJLI/01/03 - AA04271), to run in April 2003, and the screening dates
for the Menthol study. Please note that the IRB dates has been revised to 11
March, with final documents needed on 05 March.

As you mentioned in the conference call this morning, we may be looking at a
continuation onto the Menthol. Philip Morris may have a decision on this on
Friday.

This morning, MDS was also asked to provide another set of dates for a 10-day
study, due to possibly not having animal data back in time for the initial
Series K study (Jun). (Phil, would you be able to provide 10 days in September
2003? To be used if Jun study does not go). Dates for a continuation on to
both Series K studies will also be needed, but at a later date.

Thanks
Kim

Kimberly M. Prchal
Senior Project Manager
MDS Pharma Services - Lincoln, NE
kimberly.prchal@mdsps.com
402.437.4773